Ambrx Biopharma Inc ADR (AMAM)

$10.13 0.00 (0.00%)

19:00 EDT AMAM Stock Quote Delayed 30 Minutes

3 Stocks to Buy That Are Up 200% or More in 2024

By Jeremy Flint, InvestorPlace Contributor Feb 23, 2024

Each of these stocks up 200% in 2024 offer unique upside opportunities for investors, including equity arbitrage plays.

Why Is Ambrx Biopharma (AMAM) Stock Up 100% Today?

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

7 Cheap Stocks That Are Worth Your Attention

More Articles

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.)

Day's Range -

52-Week Range -

Dividend & Yield N/A (N/A)

AMAM Stock Predictions, Articles, and Ambrx Biopharma Inc ADR News

From InvestorPlace
From the Web

7 Risky Stocks That Are Worth the Stretch

By Louis Navellier and the InvestorPlace Research Staff Mar 31, 2023

If you're going to invest in risky stocks, it's important for you to first understand your risk tolerance. These names will get you started.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

By William White, InvestorPlace Writer Feb 27, 2023

We're starting off Monday with a breakdown of the biggest pre-market stock movers investors will want to keep an eye on!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

By William White, InvestorPlace Writer Feb 24, 2023

It's time to start off trading on Friday with a breakdown of the biggest pre-market stock movers worth keeping an eye on!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer Feb 22, 2023

We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to watch on Wednesday morning!

Why Is Ambrx Biopharma (AMAM) Stock Down 15% Today?

By William White, InvestorPlace Writer Feb 17, 2023

Ambrx Biopharma (AMAM) stock is falling on Friday but it's not due to any negative news released by the medical company today.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

By William White, InvestorPlace Writer Feb 17, 2023

We're starting off the final trading day of the week with a look at the biggest pre-market stock movers worth watching on Friday!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

By William White, InvestorPlace Writer Dec 13, 2022

We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about for Tuesday morning!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

By William White, InvestorPlace Writer Dec 12, 2022

We're starting off the week with a look at the biggest pre-market stock movers traders need to know about for Monday morning!

Why Is Ambrx (AMAM) Stock Up 400% Today?

By Chris MacDonald, InvestorPlace Contributor Dec 9, 2022

Today, shareholders in early-stage biotech company Ambrx and AMAM stock are seeing significant gains in this volatile session.

Better Growth Stock: UnitedHealth Group vs. Johnson & Johnson

From The Motley Fool Jan 27, 2024

These companies have been focusing on growing their operations, but which stock is likely to provide investors with better returns?

Barron’s cites cancer and weight loss plays for biotech M&A (NASDAQ:VKTX)

From Seeking Alpha Jan 9, 2024

On the back of recent deals involving big pharma, Barron’s issued positive remarks on a possible acceleration of biotech M&A activity on Tuesday. Read more here.

Ambrx Holders Who Bought for Pennies See 6,700% Gain on J&J Bid

From Bloomberg Jan 9, 2024

Longtime believers in Ambrx Biopharma Inc. are being rewarded with juicy returns as Johnson & Johnson’s buyout offer values the biotech stock at more than 6,700% of its all-time low.

Johnson & Johnson to acquire Ambrx Biopharma (NYSE:JNJ)

From Seeking Alpha Jan 8, 2024

Johnson & Johnson (JNJ) to acquire Ambrx Biopharma (AMAM) for around $2B in a deal to boost its drug pipeline with antibody-drug conjugates. (ADCs). Read more here.

J&J to Purchase Tumor-Antibody Biotech Ambrx for $2 Billion

From Bloomberg Jan 8, 2024

Johnson & Johnson will pay $2 billion in cash to acquire Ambrx Biopharma Inc., gaining widely sought drugs that target tumors with lethal drugs.

Why Shares of Ambrx Biopharma Soared This Week

From The Motley Fool Sep 21, 2023

A big buy by an asset manager spurred interest in the biotech stock.

ADVERTISEMENT